Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Ultragenyx Pharmaceutical Inc. (RARE)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $673.0M | $560.0M | $434.0M | $363.3M | $351.4M | $271.0M | $103.7M | $51.5M | $2.6M | $133,000 | — | — | — | — |
| Research & development | $750.0M | $698.0M | $648.0M | $705.8M | $497.2M | $412.1M | $357.4M | $294.0M | $231.6M | $183.2M | $114.7M | $46.0M | $27.8M | $12.6M |
| Operating expenses | — | — | — | — | — | $601.1M | $527.9M | $422.9M | $331.6M | $248.1M | $147.7M | $56.8M | $32.3M | $16.0M |
| Operating income | −$535.0M | −$536.0M | −$569.0M | −$648.9M | −$381.7M | −$330.1M | −$424.2M | −$371.4M | −$328.9M | −$248.0M | −$147.7M | −$56.8M | −$32.3M | −$16.0M |
| EBITDAderived | −$500.0M | −$500.0M | −$543.0M | −$630.7M | −$368.5M | −$317.9M | −$415.6M | −$351.8M | −$323.1M | −$244.6M | −$146.4M | −$56.1M | −$31.8M | −$15.7M |
| Net income | −$575.0M | −$569.0M | −$607.0M | −$707.4M | −$454.0M | −$186.6M | −$402.7M | −$197.6M | −$302.1M | −$245.9M | −$145.6M | −$59.8M | −$35.1M | −$16.3M |
| Basic EPSper diluted share | -$5.83 | -$6.29 | -$8.25 | -$10.12 | -$6.70 | -$3.07 | -$7.12 | -$3.97 | -$7.12 | -$6.21 | -$3.96 | -$2.25 | -$14.87 | -$14.20 |
| Diluted EPSper diluted share | -$5.83 | -$6.29 | -$8.25 | -$10.12 | -$6.70 | -$3.07 | -$7.12 | -$3.97 | -$7.12 | -$6.21 | -$3.96 | -$2.25 | -$14.87 | -$14.20 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 15, 2026Form 4 | Sanders Corazon (Corsee) D.Director | SellCommon Stock | 2.0K | $25.05 | $50.1K | 21.1K |
| Jun 15, 2026Form 4 · 10b5-1 | Parschauer Karah HerdmanEVP and Chief Legal Officer | SellCommon Stock | 1.9K | $24.62 | $46.8K | 94.5K |
| Jun 1, 2026Form 4 · 10b5-1 | Horn HowardChief Financial Officer | SellCommon Stock | 4.7K | $23.77 | $110.6K | 105.7K |
| May 18, 2026Form 4 · 10b5-1 | SULIMAN SHEHNAAZDirector | SellCommon Stock | 5.7K | $25.12 | $144.2K | 28.0K |
| May 5, 2026Form 4 | Crombez EricEVP and Chief Medical Officer | SellCommon Stock | 344 | $24.96 | $8.6K | 111.2K |